Douglas Pharmaceuticals Limited

Peter William Surman

Natalie June Medlicott

Paul William Glue

Ian Hampson

Lynne Hampson

Yuefeng Long

Fergus Cameron Binnie

Sharon Ferguson

Wai Bik Mak

Andrew Douglas McLeod

Andrew Douglas Mcleod

Sharon Houlder-Levell

The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

Extended release pharmaceutical formulation

Provided herein are methods and compositions for treating and/or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV) infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir, methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and/or inhibiting the progression of HSV related conditions.

Compositions comprising lopinavir and treatment of conditions

The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.

Extended release pharmaceutical formulation and methods of treatment

The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

The invention provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

A physicochemically stable aqueous composition including clozapine suspension.

Growing community of inventors

Auckland, New Zealand

Peter William Surman